At the time of writing, IGM Biosciences Inc [IGMS] stock is trading at $1.29, up 15.18%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IGMS shares have gain 9.32% over the last week, with a monthly amount glided 1.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IGM Biosciences Inc [NASDAQ: IGMS] stock has seen the most recent analyst activity on January 10, 2025, when Stifel downgraded its rating to a Hold and also revised its price target to $2.50 from $27. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on January 10, 2025, and dropped its price target to $1.50. On January 10, 2025, downgrade downgraded it’s rating to Underweight and revised its price target to $2 on the stock. Guggenheim downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2 on January 10, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on December 06, 2024, and assigned it a price target of $21. In a note dated October 01, 2024, Truist downgraded an Hold rating on this stock and revised its target price from $24 to $12.
For the past year, the stock price of IGM Biosciences Inc fluctuated between $0.92 and $22.50. Currently, Wall Street analysts expect the stock to reach $1.75 within the next 12 months. IGM Biosciences Inc [NASDAQ: IGMS] shares were valued at $1.29 at the most recent close of the market. An investor can expect a potential return of 35.66% based on the average IGMS price forecast.
Analyzing the IGMS fundamentals
According to IGM Biosciences Inc [NASDAQ:IGMS], the company’s sales were 2.68M for trailing twelve months, which represents an 0.40% jump. Gross Profit Margin for this corporation currently stands at -0.73% with Operating Profit Margin at -78.14%, Pretax Profit Margin comes in at -74.18%, and Net Profit Margin reading is -74.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.96, Equity is -3.18 and Total Capital is -1.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of62.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2567 points at the first support level, and at 1.2233 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3567, and for the 2nd resistance point, it is at 1.4233.
Ratios To Look Out For
It is important to note that IGM Biosciences Inc [NASDAQ:IGMS] has a current ratio of 5.71. In addition, the Quick Ratio stands at 5.71 and the Cash Ratio stands at 1.31. Considering the valuation of this stock, the price to sales ratio is 28.94, the price to book ratio is 111.02.
Transactions by insiders
Recent insider trading involved Weber Steven, PRINCIPAL ACCOUNTING OFFICER, that happened on Jun 16 ’25 when 486.0 shares were sold. CHIEF FINANCIAL OFFICER, Tahir Misbah completed a deal on Jun 16 ’25 to sell 1522.0 shares. Meanwhile, Chief Executive Officer Harler Mary Beth sold 1522.0 shares on Jun 16 ’25.
